- Home
- CMBM vs LEXX Comparison
CMBM vs LEXX Comparison
Compare CMBM & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMBM
- LEXX
- Stock Information
- Founded
- CMBM 2011
- LEXX 2004
- Country
- CMBM United States
- LEXX Canada
- Employees
- CMBM N/A
- LEXX N/A
- Industry
- CMBM Radio And Television Broadcasting And Communications Equipment
- LEXX Biotechnology: Pharmaceutical Preparations
- Sector
- CMBM Technology
- LEXX Health Care
- Exchange
- CMBM Nasdaq
- LEXX Nasdaq
- Market Cap
- CMBM 50.8M
- LEXX 43.5M
- IPO Year
- CMBM 2019
- LEXX N/A
- Fundamental
- Price
- CMBM $1.16
- LEXX $2.01
- Analyst Decision
- CMBM Strong Buy
- LEXX Strong Buy
- Analyst Count
- CMBM 3
- LEXX 2
- Target Price
- CMBM $5.50
- LEXX $11.00
- AVG Volume (30 Days)
- CMBM 91.4K
- LEXX 148.5K
- Earning Date
- CMBM 11-07-2024
- LEXX 01-10-2025
- Dividend Yield
- CMBM N/A
- LEXX N/A
- EPS Growth
- CMBM N/A
- LEXX N/A
- EPS
- CMBM N/A
- LEXX N/A
- Revenue
- CMBM $172,215,000.00
- LEXX $411,019.00
- Revenue This Year
- CMBM N/A
- LEXX $82.02
- Revenue Next Year
- CMBM $18.55
- LEXX $95.09
- P/E Ratio
- CMBM N/A
- LEXX N/A
- Revenue Growth
- CMBM N/A
- LEXX 34.05
- 52 Week Low
- CMBM $1.08
- LEXX $1.20
- 52 Week High
- CMBM $6.50
- LEXX $6.85
- Technical
- Relative Strength Index (RSI)
- CMBM 38.76
- LEXX 26.93
- Support Level
- CMBM $1.12
- LEXX $2.20
- Resistance Level
- CMBM $1.29
- LEXX $2.42
- Average True Range (ATR)
- CMBM 0.10
- LEXX 0.19
- MACD
- CMBM 0.00
- LEXX -0.00
- Stochastic Oscillator
- CMBM 10.53
- LEXX 7.27
About CMBM Cambium Networks Corporation
Cambium Networks Corp provides wireless broadband networking infrastructure solutions for network operators, including medium-sized wireless Internet service providers, enterprises, and government agencies. The company geographically operates in North America; Europe, Middle East and Africa; Caribbean and Latin America; and Asia Pacific. It derives maximum revenue from North America.
About LEXX Lexaria Bioscience Corp.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH has the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. The Company has four reportable segments: Intellectual Property Licensing, B2B Production, Research and Development and Corporate. It earns maximum revenue from Intellectual Property Licensing.